Nature Communications (Jan 2022)

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

  • Derek P. Wong,
  • Nand K. Roy,
  • Keman Zhang,
  • Anusha Anukanth,
  • Abhishek Asthana,
  • Nicole J. Shirkey-Son,
  • Samantha Dunmire,
  • Bryan J. Jones,
  • Walker S. Lahr,
  • Beau R. Webber,
  • Branden S. Moriarity,
  • Paolo Caimi,
  • Reshmi Parameswaran

DOI
https://doi.org/10.1038/s41467-021-27853-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 17

Abstract

Read online

Antigen escape represents a potential drawback of chimeric antigen receptor T cell (CAR-T) therapy targeting a single tumor-associated antigen. To reduce the risk of antigen escape, here the authors report the design and characterization of a BAFF ligand CAR-T that can recognize three different receptors (BAFF-R, BCMA and TACI), demonstrating in vitro and in vivo cytotoxicity against multiple B cell cancer models.